Skip to main content
PMC home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 2003 May;79(931):268–271. doi: 10.1136/pmj.79.931.268

Mechanisms and management of diuretic resistance in congestive heart failure

L K M De Bruyne
PMCID: PMC1742703  PMID: 12782772

Abstract

Diuretic drugs are used almost universally in patients with congestive heart failure, most frequently the potent loop diuretics. Despite their unproven effect on survival, their indisputable efficacy in relieving congestive symptoms makes them first line therapy for most patients. In the treatment of more advanced stages of heart failure diuretics may fail to control salt and water retention despite the use of appropriate doses. Diuretic resistance may be caused by decreased renal function and reduced and delayed peak concentrations of loop diuretics in the tubular fluid, but it can also be observed in the absence of these pharmacokinetic abnormalities. When the effect of a short acting diuretic has worn off, postdiuretic salt retention will occur during the rest of the day. Chronic treatment with a loop diuretic results in compensatory hypertrophy of epithelial cells downstream from the thick ascending limb and consequently its diuretic effect will be blunted. Strategies to overcome diuretic resistance include restriction of sodium intake, changes in dose, changes in timing, and combination diuretic therapy.

Full Text

The Full Text of this article is available as a PDF (90.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abrams J. Intramuscular bumetanide and furosemide in congestive heart failure. J Clin Pharmacol. 1981 Nov-Dec;21(11-12):673–679. doi: 10.1002/j.1552-4604.1981.tb05682.x. [DOI] [PubMed] [Google Scholar]
  2. Brater D. C., Chennavasin P., Seiwell R. Furosemide in patients with heart failure: shift in dose-response curves. Clin Pharmacol Ther. 1980 Aug;28(2):182–186. doi: 10.1038/clpt.1980.148. [DOI] [PubMed] [Google Scholar]
  3. Brater D. C., Day B., Burdette A., Anderson S. Bumetanide and furosemide in heart failure. Kidney Int. 1984 Aug;26(2):183–189. doi: 10.1038/ki.1984.153. [DOI] [PubMed] [Google Scholar]
  4. Channer K. S., McLean K. A., Lawson-Matthew P., Richardson M. Combination diuretic treatment in severe heart failure: a randomised controlled trial. Br Heart J. 1994 Feb;71(2):146–150. doi: 10.1136/hrt.71.2.146. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dormans T. P., Gerlag P. G. Combination of high-dose furosemide and hydrochlorothiazide in the treatment of refractory congestive heart failure. Eur Heart J. 1996 Dec;17(12):1867–1874. doi: 10.1093/oxfordjournals.eurheartj.a014805. [DOI] [PubMed] [Google Scholar]
  6. Dormans T. P., van Meyel J. J., Gerlag P. G., Tan Y., Russel F. G., Smits P. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol. 1996 Aug;28(2):376–382. doi: 10.1016/0735-1097(96)00161-1. [DOI] [PubMed] [Google Scholar]
  7. Ellison D. H. Diuretic resistance: physiology and therapeutics. Semin Nephrol. 1999 Nov;19(6):581–597. [PubMed] [Google Scholar]
  8. Ferguson J. A., Sundblad K. J., Becker P. K., Gorski J. C., Rudy D. W., Brater D. C. Role of duration of diuretic effect in preventing sodium retention. Clin Pharmacol Ther. 1997 Aug;62(2):203–208. doi: 10.1016/S0009-9236(97)90069-2. [DOI] [PubMed] [Google Scholar]
  9. Fliser D., Schröter M., Neubeck M., Ritz E. Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure. Kidney Int. 1994 Aug;46(2):482–488. doi: 10.1038/ki.1994.298. [DOI] [PubMed] [Google Scholar]
  10. Gerlag P. G., van Meijel J. J. High-dose furosemide in the treatment of refractory congestive heart failure. Arch Intern Med. 1988 Feb;148(2):286–291. [PubMed] [Google Scholar]
  11. Kaissling B., Stanton B. A. Adaptation of distal tubule and collecting duct to increased sodium delivery. I. Ultrastructure. Am J Physiol. 1988 Dec;255(6 Pt 2):F1256–F1268. doi: 10.1152/ajprenal.1988.255.6.F1256. [DOI] [PubMed] [Google Scholar]
  12. Kirchner K. A., Martin C. J., Bower J. D. Prostaglandin E2 but not I2 restores furosemide response in indomethacin-treated rats. Am J Physiol. 1986 Jun;250(6 Pt 2):F980–F985. doi: 10.1152/ajprenal.1986.250.6.F980. [DOI] [PubMed] [Google Scholar]
  13. Kiyingi A., Field M. J., Pawsey C. C., Yiannikas J., Lawrence J. R., Arter W. J. Metolazone in treatment of severe refractory congestive cardiac failure. Lancet. 1990 Jan 6;335(8680):29–31. doi: 10.1016/0140-6736(90)90148-x. [DOI] [PubMed] [Google Scholar]
  14. Kuchar D. L., O'Rourke M. F. High dose furosemide in refractory cardiac failure. Eur Heart J. 1985 Nov;6(11):954–958. doi: 10.1093/oxfordjournals.eurheartj.a061793. [DOI] [PubMed] [Google Scholar]
  15. Lahav M., Regev A., Ra'anani P., Theodor E. Intermittent administration of furosemide vs continuous infusion preceded by a loading dose for congestive heart failure. Chest. 1992 Sep;102(3):725–731. doi: 10.1378/chest.102.3.725. [DOI] [PubMed] [Google Scholar]
  16. Levine M. G., McGill C. C., Ahlberg A. W., White M. P., Giri S., Shareef B., Waters D., Heller G. V. Functional assessment with electrocardiographic gated single-photon emission computed tomography improves the ability of technetium-99m sestamibi myocardial perfusion imaging to predict myocardial viability in patients undergoing revascularization. Am J Cardiol. 1999 Jan 1;83(1):1–5. doi: 10.1016/s0002-9149(98)00772-3. [DOI] [PubMed] [Google Scholar]
  17. Loon N. R., Wilcox C. S., Unwin R. J. Mechanism of impaired natriuretic response to furosemide during prolonged therapy. Kidney Int. 1989 Oct;36(4):682–689. doi: 10.1038/ki.1989.246. [DOI] [PubMed] [Google Scholar]
  18. Neuberg Gerald W., Miller Alan B., O'Connor Chris M., Belkin Robert N., Carson Peter E., Cropp Anne B., Frid David J., Nye Regina G., Pressler Milton L., Wertheimer John H. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J. 2002 Jul;144(1):31–38. doi: 10.1067/mhj.2002.123144. [DOI] [PubMed] [Google Scholar]
  19. Packer M. Pathophysiology of chronic heart failure. Lancet. 1992 Jul 11;340(8811):88–92. doi: 10.1016/0140-6736(92)90405-r. [DOI] [PubMed] [Google Scholar]
  20. Pitt B., Zannad F., Remme W. J., Cody R., Castaigne A., Perez A., Palensky J., Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999 Sep 2;341(10):709–717. doi: 10.1056/NEJM199909023411001. [DOI] [PubMed] [Google Scholar]
  21. Rybak L. P. Ototoxicity of loop diuretics. Otolaryngol Clin North Am. 1993 Oct;26(5):829–844. [PubMed] [Google Scholar]
  22. Sagar S., Sharma B. K., Sharma P. L., Wahi P. L. A comparative randomized double-blind clinical trial of bumetanide and furosemide in congestive cardiac failure and other edema states. Int J Clin Pharmacol Ther Toxicol. 1984 Sep;22(9):473–478. [PubMed] [Google Scholar]
  23. Schrier R. W., Abraham W. T. Hormones and hemodynamics in heart failure. N Engl J Med. 1999 Aug 19;341(8):577–585. doi: 10.1056/NEJM199908193410806. [DOI] [PubMed] [Google Scholar]
  24. Stanton B. A., Kaissling B. Adaptation of distal tubule and collecting duct to increased Na delivery. II. Na+ and K+ transport. Am J Physiol. 1988 Dec;255(6 Pt 2):F1269–F1275. doi: 10.1152/ajprenal.1988.255.6.F1269. [DOI] [PubMed] [Google Scholar]
  25. Vargo D. L., Kramer W. G., Black P. K., Smith W. B., Serpas T., Brater D. C. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther. 1995 Jun;57(6):601–609. doi: 10.1016/0009-9236(95)90222-8. [DOI] [PubMed] [Google Scholar]
  26. Vasko M. R., Cartwright D. B., Knochel J. P., Nixon J. V., Brater D. C. Furosemide absorption altered in decompensated congestive heart failure. Ann Intern Med. 1985 Mar;102(3):314–318. doi: 10.7326/0003-4819-102-3-314. [DOI] [PubMed] [Google Scholar]
  27. van Meyel J. J., Smits P., Dormans T., Gerlag P. G., Russel F. G., Gribnau F. W. Continuous infusion of furosemide in the treatment of patients with congestive heart failure and diuretic resistance. J Intern Med. 1994 Apr;235(4):329–334. doi: 10.1111/j.1365-2796.1994.tb01082.x. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES